Combination Of PAXIL Tablet And Benzodiazepines
Launched by GLAXOSMITHKLINE · Nov 30, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patients with depression or depressive episodes who are diagnosed to have major depressive disorders according to the DSM-IV criteria.
- • Patients with 14 or higher points in total scores for Items No.1 - 17 on HAM-D.
- • Patients who have continuously received Benzodiazepine anxiolytics.
- Exclusion criteria:
- • Patients with a strong suicide tendency.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
, ,
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials